SEC Form 4 · accession 0001209191-15-049534
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick G Enright
Director
Period of report
Jun 1, 2015
Accepted (ET)
Jun 3, 2015 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jun 1, 2015 | S | 1,960 | $177.8168 | D | 301,951 | I | By Longitude Venture Partners, L.P. |
| Ordinary SharesF3,F2 | Jun 1, 2015 | S | 5,447 | $178.7562 | D | 296,504 | I | By Longitude Venture Partners, L.P. |
| Ordinary SharesF4,F2 | Jun 1, 2015 | S | 2,397 | $179.4322 | D | 294,107 | I | By Longitude Venture Partners, L.P. |
| Ordinary SharesF5,F2 | Jun 1, 2015 | S | 40 | $177.8168 | D | 6,049 | I | By Longitude Capital Associates, L.P. |
| Ordinary SharesF6,F2 | Jun 1, 2015 | S | 109 | $178.7594 | D | 5,940 | I | By Longitude Capital Associates, L.P. |
| Ordinary SharesF7,F2 | Jun 1, 2015 | S | 47 | $179.4296 | D | 5,893 | I | By Longitude Capital Associates, L.P. |
| Ordinary Shares | holding | — | — | — | 1,650 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $177.25 to $178.15. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F2The Reporting Person is a managing member of Longitude Capital Partners, LLC, the general partner of each of Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. The Reporting Person disclaims beneficial ownership of the securities of the Issuer held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. except to the extent of his pecuniary interest therein.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $178.25 to $179.21. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $179.26 to $179.73. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $177.25 to $178.15. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F6Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $178.25 to $179.21. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F7Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $179.26 to $179.73. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Remarks
All of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.